RecruitingNot ApplicableNCT04210284

Oral Nutritional Optimization in Total Joint Arthroplasty


Sponsor

NYU Langone Health

Enrollment

72 participants

Start Date

Jul 6, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to determine the effect on hematological markers of nutritional intervention on nutritionally deficient patients following total joint replacement surgery.


Eligibility

Min Age: 55 Years

Inclusion Criteria4

  • Patient are current candidates for elective primary total hip and total knee arthroplasty
  • Patients ≥55 years of age but ≤ 95
  • Patients who meet at least one of the following three laboratory criteria for malnutrition:
  • TSerum Albumin: ≤3.5 mg/dl Pre-Albumin: <15 mg/dl Transferrin: <200 mg/dl

Exclusion Criteria7

  • Previous history of septic arthritis
  • Allergy to oral supplementation
  • Inability to consume oral supplementation
  • Protein malabsorption syndromes
  • Eating disorders
  • End stage renal and hepatic disease
  • Revision surgery, non-elective surgery, hemiarthroplasty, and unicompartmental knee arthroplasty

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTEnsure

Ensure Max Protein Shake is an over the counter available drinkable nutritional supplement. Per serving, it contains: * 160 Calories, 20 from fat * 2g Total fat * 0.5g Saturated fat * 20mg Cholesterol * 135mg Sodium * 170mg Potassium * 19g Total carbohydrate * \<1g Fiber * 4g Sugar * 16g Protein Participants will receive Ensure High Protein for 2 weeks pre- and 4 weeks post-operatively. These patients will be instructed to consume 1 serving (16fl oz) of Ensure High Protein daily. They will be provided with this product at a pre-operative clinical visit or have it mailed to their home. Hematologic nutritional values will be measured as specified previously. Descriptive statistics will be used to report baseline characteristics and primary study objectives. Hematologic outcomes will be compared between the control ("NO ENSURE") and oral supplementation ("ENSURE") arms for the aforementioned baseline and perioperative variables


Locations(2)

NYU Langone Health

New York, New York, United States

Rothman Orthopedic Institute

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04210284


Related Trials